$2.62
0.01[0.38%]
At close: Apr 26
$2.62
0[0.00%]
After Hours: 4:32PM EDT
BioXcel Therapeutics
(NASDAQ:BTAI)Latest News for BioXcel Therapeutics Stock (NASDAQ:BTAI)
BioXcel Therapeutics Stock (NASDAQ: BTAI)
Categories: All
Tuesday, April 23, 2024
Monday, April 22, 2024
Wednesday, April 10, 2024
Monday, March 25, 2024
Monday, March 18, 2024
Thursday, March 14, 2024
Wednesday, March 13, 2024
Tuesday, March 12, 2024
- BioXcel Therapeutics shares are trading higher after the company reported better-than-expected Q4 GAAP EPS results.Benzinga Newsdesk - Mar 12, 2024, 9:08AM
- BioXcel Therapeutics' Cash And Cash Equivalents Totaled $65.2M Which Is Expected To Provide Cash Runway Through Mid-2024Benzinga Newsdesk - Mar 12, 2024, 7:04AM
- BioXcel Therapeutics Q4 GAAP EPS $(0.76) Beats $(0.91) Estimate, Sales $376.00K Miss $710.00K EstimateBenzinga Newsdesk - Mar 12, 2024, 7:03AM
- Earnings Scheduled For March 12, 2024Benzinga Insights - Mar 12, 2024, 5:35AM
Monday, March 11, 2024
Tuesday, February 27, 2024
Wednesday, February 14, 2024
Tuesday, February 13, 2024
Monday, February 12, 2024
Friday, February 09, 2024
- 12 Health Care Stocks Moving In Friday's After-Market SessionBenzinga Insights - Feb 9, 2024, 4:31PM
- Why Take-Two Interactive Software Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Friday's Mid-Day SessionAvi Kapoor - Feb 9, 2024, 1:18PM
- 12 Health Care Stocks Moving In Friday's Intraday SessionBenzinga Insights - Feb 9, 2024, 12:31PM
- Why BioXcel Therapeutics Shares Are Falling TodayNabaparna Bhattacharya - Feb 9, 2024, 11:05AM
- S&P 500 Tops 5,000; PepsiCo Posts Upbeat EarningsAvi Kapoor - Feb 9, 2024, 9:45AM
- BioXcel Therapeutics shares are trading lower after the company announced a proposed public offering.Benzinga Newsdesk - Feb 9, 2024, 8:45AM
- 12 Health Care Stocks Moving In Friday's Pre-Market SessionBenzinga Insights - Feb 9, 2024, 8:06AM
- Why Cloudflare Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving PremarketAvi Kapoor - Feb 9, 2024, 7:52AM
Thursday, February 08, 2024
- BioXcel Therapeutics shares are trading lower after the company announced a proposed public offering.Benzinga Newsdesk - Feb 8, 2024, 5:11PM
- 12 Health Care Stocks Moving In Thursday's After-Market SessionBenzinga Insights - Feb 8, 2024, 4:31PM
- BioXcel Therapeutics Commences Public Offering Of $60M Of Shares Of Its Common StockBenzinga Newsdesk - Feb 8, 2024, 4:04PM
Monday, February 05, 2024
- BioXcel shares are trading higher after the company reported the USPTO has allowed U.S. Patent Application No. 17/496,470 with claims pertaining to a method of treating agitation in Alzheimer's disease using the oromucosal formulations of dexmedetomidine.Benzinga Newsdesk - Feb 5, 2024, 11:51AM
- United States Patent And Trademark Office Has Allowed U.S. Patent Application No. 17/496,470 Related To Treating Agitation In Patients With Alzheimer's Disease Using BioXcel Therapeutics' 60 mcg Oromucosal (Dexmedetomidine) In Water-soluble Dosage FormBenzinga Newsdesk - Feb 5, 2024, 7:05AM
Wednesday, November 15, 2023
Tuesday, November 14, 2023
- BioXcel Therapeutics shares are trading lower after the company reported worse-than-expected Q3 financial results.Benzinga Newsdesk - Nov 14, 2023, 2:06PM
- Why Beyond Air Shares Are Trading Lower By Around 37%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionLisa Levin - Nov 14, 2023, 2:05PM
- Why Is Dementia Focused BioXcel Therapeutics Stock Trading Lower Today?Vandana Singh - Nov 14, 2023, 2:01PM
- On Nov.13, BioXcel Therapeutics Reported Q3 Adjusted EPS $(1.58) Misses $(1.31) Estimate, Sales $341.00K Miss $670.00K EstimateBenzinga Newsdesk - Nov 14, 2023, 9:47AM
- Earnings Scheduled For November 14, 2023Benzinga Insights - Nov 14, 2023, 8:23AM
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga Insights - Nov 14, 2023, 8:06AM
- Recap: BioXcel Therapeutics Q3 EarningsBenzinga Insights - Nov 14, 2023, 7:15AM
- BioXcel Therapeutics Aligns With FDA Recommendation For Phase 3 Trial For TRANQUILITY Program To Support Potential sNDA For Acute Treatment Of Agitation Associated With Dementia Due To Probable Alzheimer's DiseaseBenzinga Newsdesk - Nov 14, 2023, 7:06AM
Monday, November 13, 2023
Wednesday, November 08, 2023
- BioXcel Therapeutics Reveals Survival Data From Prostate Cancer Combo Therapy TrialVandana Singh - Nov 8, 2023, 3:15PM
- Bioxcel Therapeutics Announced Overall Survival Data From Its Phase 2 Trial Of BXCL701 Plus Keytruda For Metastatic Castration-resistant Prostate Cancer, Showed A Median Overall Survival Of 15.5 Months And A 12-month Survival Rate Of 59%Benzinga Newsdesk - Nov 8, 2023, 7:19AM